Clinical Trial Results:
STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL
PANCREATIC CANCER PERSISTING AFTER SURGICAL EXCISION
Summary
|
|
EudraCT number |
2012-003528-19 |
Trial protocol |
DE |
Global end of trial date |
13 Jun 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Mar 2020
|
First version publication date |
11 Mar 2020
|
Other versions |
|
Summary report(s) |
Statement STEM PACE 2012-003528-19 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
STEM PACE
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN47877138 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and Acting Business Director
|
||
Sponsor organisation address |
Im Neuenheimer Feld 672, Heidelberg, Germany,
|
||
Public contact |
Clinic of General Surgery, University Hospital Heidelberg, +49 62215639491,
|
||
Scientific contact |
Clinic of General Surgery, University Hospital Heidelberg, +49 62215639491,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Jun 2016
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Jun 2016
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The overall objective of this trial is to generate for the first time state-of-the-art scientific clinical evidence that allo-HSCT is feasible and can provide long-term disease control in patients with effectively resected pancreatic adenocarcinoma and may have the potential to change the natural course of this otherwise fatal malignancy.
|
||
Protection of trial subjects |
N/A
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
05 Nov 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 99999
|
||
Worldwide total number of subjects |
99999
|
||
EEA total number of subjects |
99999
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
99999
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial. | ||||||
Pre-assignment
|
|||||||
Screening details |
N/A | ||||||
Period 1
|
|||||||
Period 1 title |
overall trial (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
N/A
|
||||||
Arms
|
|||||||
Arm title
|
Allo-HSCT | ||||||
Arm description |
allogeneic hematopoietic stem cell transplantation | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Allogeneic hematopoietic stem cells
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Suspension for injection
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
N/A
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Allo-HSCT
|
||
Reporting group description |
allogeneic hematopoietic stem cell transplantation |
|
|||||||
End point title |
2-year progression-free survival (PFS) from registration. [1] | ||||||
End point description |
99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled
in the Trial.
|
||||||
End point type |
Primary
|
||||||
End point timeframe |
N/A
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: 99999 is "Not applicable" value or 0 participants, this trial was discontinued with no participants enrolled in the trial. No statistical analyses for this end point. |
|||||||
|
|||||||
Notes [2] - No subjects were enrolled in the trial hence results are not available. |
|||||||
No statistical analyses for this end point |
|
|||||||||||
Adverse events information [1]
|
|||||||||||
Timeframe for reporting adverse events |
All adverse events occurring during the course of the clinical trial were to be collected.
|
||||||||||
Adverse event reporting additional description |
N/A
|
||||||||||
Assessment type |
Systematic | ||||||||||
Dictionary used for adverse event reporting
|
|||||||||||
Dictionary name |
MedDRA | ||||||||||
Dictionary version |
17.0
|
||||||||||
Reporting groups
|
|||||||||||
Reporting group title |
Allo-HSCT
|
||||||||||
Reporting group description |
N/A | ||||||||||
|
|||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||
|
|||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No subjects were enrolled in the trial hence results are not available . |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
25 Apr 2013 |
Clarifications and responses to subsequent demands of the Ethics Committee |
||
29 Jul 2014 |
Change of Principal Inverstigator and update of inclusion and exclusion criteria
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
No subjects were enrolled in the Trial hence results are not available. |